These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10728718)

  • 21. Bax suppresses tumorigenesis and stimulates apoptosis in vivo.
    Yin C; Knudson CM; Korsmeyer SJ; Van Dyke T
    Nature; 1997 Feb; 385(6617):637-40. PubMed ID: 9024662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Living with p53, dying of p53.
    Aylon Y; Oren M
    Cell; 2007 Aug; 130(4):597-600. PubMed ID: 17719538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 mutations promote proteasomal activity.
    Oren M; Kotler E
    Nat Cell Biol; 2016 Jul; 18(8):833-5. PubMed ID: 27463250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53-mediated apoptosis and genomic instability diseases.
    Robles AI; Harris CC
    Acta Oncol; 2001; 40(6):696-701. PubMed ID: 11765063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcription-independent p53 apoptosis: an alternative route to death.
    Speidel D
    Trends Cell Biol; 2010 Jan; 20(1):14-24. PubMed ID: 19879762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour-suppressor genes. X-rays strike p53 again.
    Vogelstein B; Kinzler KW
    Nature; 1994 Jul; 370(6486):174-5. PubMed ID: 8028656
    [No Abstract]   [Full Text] [Related]  

  • 27. Targeting mutant p53 through the mevalonate pathway.
    Freed-Pastor W; Prives C
    Nat Cell Biol; 2016 Oct; 18(11):1122-1124. PubMed ID: 27784901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-suppressor p53: implications for tumor development and prognosis.
    Kirsch DG; Kastan MB
    J Clin Oncol; 1998 Sep; 16(9):3158-68. PubMed ID: 9738588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family.
    Flores ER; Sengupta S; Miller JB; Newman JJ; Bronson R; Crowley D; Yang A; McKeon F; Jacks T
    Cancer Cell; 2005 Apr; 7(4):363-73. PubMed ID: 15837625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptional induction of protein kinase C delta by p53 tumor suppressor in the apoptotic response to DNA damage.
    Dashzeveg N; Yogosawa S; Yoshida K
    Cancer Lett; 2016 Apr; 374(1):167-174. PubMed ID: 26884258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Rho GTPase RhoE is a p53-regulated candidate tumor suppressor in cancer cells.
    Zhu Y; Zhou J; Xia H; Chen X; Qiu M; Huang J; Liu S; Tang Q; Lang N; Liu Z; Liu M; Zheng Y; Bi F
    Int J Oncol; 2014 Mar; 44(3):896-904. PubMed ID: 24399089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?
    Workman P
    Hum Exp Toxicol; 1995 Feb; 14(2):222-5. PubMed ID: 7779451
    [No Abstract]   [Full Text] [Related]  

  • 34. p53, apoptosis and radiosensitivity--experimental and clinical data.
    Weber KJ; Wenz F
    Onkologie; 2002 Apr; 25(2):136-41. PubMed ID: 12006764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas.
    Parhar P; Ezer R; Shao Y; Allen JC; Miller DC; Newcomb EW
    Brain Res Mol Brain Res; 2005 Jun; 137(1-2):98-103. PubMed ID: 15950766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families.
    Thiselton DL; Vladimirov VI; Kuo PH; McClay J; Wormley B; Fanous A; O'Neill FA; Walsh D; Van den Oord EJ; Kendler KS; Riley BP
    Biol Psychiatry; 2008 Mar; 63(5):449-57. PubMed ID: 17825267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of the tumor suppressor ARF in oncogenesis].
    Pimkina IuS; Dorosevich AE
    Arkh Patol; 2009; 71(1):60-3. PubMed ID: 19514363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Need for clarification of data in a recent meta-analysis about TP53 codon 72 polymorphism and cancer susceptibility.
    Lu PH; Wei MX; Li C; Shen W; Chen MB
    Carcinogenesis; 2011 Mar; 32(3):443; author reply 444. PubMed ID: 21135152
    [No Abstract]   [Full Text] [Related]  

  • 39. Hzf and hCAS/CSE1L: making the right choice in p53-mediated tumour suppression.
    Ewings KE; Ryan KM
    Cell Res; 2007 Oct; 17(10):829-31. PubMed ID: 17934491
    [No Abstract]   [Full Text] [Related]  

  • 40. p53 and human cancers.
    Lane DP
    Br Med Bull; 1994 Jul; 50(3):582-99. PubMed ID: 7987642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.